🇺🇸 FDA

Company profile · Sponsor

Santen

Santen Oy

E24528E · EMA pharma TAMPERE, FI
Pipeline
3
Drugs
0
Patents
0

Quick answer

Santen (E24528E) is a pharma company. headquartered in TAMPERE, FI. listed on EMA. NovaPharmaNews links 3 pipeline programs, 0 drugs, and 0 patents to this profile..

Company facts

Ticker E24528E
Exchange EMA
Company type pharma
Headquarters TAMPERE, FI

Pipeline (3)

Search pipeline →

  1. Betamethasone Microsphere (DE-102） Low Dose

    Santen

    Diabetic Macular Edema

    phase 3 small molecule completed

    1 trial

  2. Placebo to OXYMETAZOLINE HYDROCHLORIDE (Vehicle), STN1013800

    Santen

    Acquired Blepharoptosis

    phase 3 small molecule active

    1 trial

  3. STN1010904, Placebo (vehicle), STN1010904

    Santen

    Fuchs Endothelial Corneal Dystrophy (FECD)

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is Santen?

Santen (E24528E) is a pharma company. headquartered in TAMPERE, FI. listed on EMA. NovaPharmaNews links 3 pipeline programs, 0 drugs, and 0 patents to this profile..

What pipeline programs does Santen sponsor?

We track 3 ClinicalTrials.gov-linked programs for Santen, including Betamethasone Microsphere (DE-102） Low Dose and 2 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Santen company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.